Regeneron Pharmaceuticals Accounts Payable

Regeneron Pharmaceuticals (REGN) currently reports a accounts payable of $1B as of March 2026. That compares with $710M in the prior-year period — up 45.6% year over year. Use the charts on this page to explore Regeneron Pharmaceuticals's accounts payable history and peer comparisons.

Regeneron Pharmaceuticals's accounts payable increased from $710M to $1B — a 45.6% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Regeneron Pharmaceuticals reported $1B in accounts payable as of March 2026. That compares with $710M in the prior-year period — up 45.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $1B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Regeneron Pharmaceuticals, and consider following REGN for alerts when major investors trade the stock.

Regeneron Pharmaceuticals is classified in the Healthcare sector. On accounts payable, it currently shows $1B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing REGN with unrelated industries.